Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1789972 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $17.52Day +1.80%Mkt cap $1.1B1Y +114.7%Off 52W high −9.8%Vol (1Y) 80.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,025 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest16.7% of sh out |
| Days to cover15.2d |
| 13F net flow (QoQ)+1.18% |
| Top-10 13F concentration61.9% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$0 |
| Earnings (TTM)-$221.0M |
| ROE−44.0% |
| ROIC−171.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+69.3% |
| 1Y+114.7% |
| 3Y+65.4% |
| 5Y−23.6% |
| 10Y+24928.6% |
| Since incept. (ann.)+25.1% |
Total return through 2026-07-30 · series begins 2011-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)80.3% |
| Ann. volatility (3Y)69.2% |
| Sharpe (1Y)1.32 |
| Sharpe (3Y)0.58 |
| Max drawdown (1Y)−31.1% |
| Max drawdown (3Y)−80.4% |
| Beta (3Y vs SPY)−0.58 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 9.0M | $127M | 14.81% | +0.0% |
| MPM BIOIMPACT LLC | 7.6M | $109M | 12.64% | +0.0% |
| BVF INC/IL | 5.8M | $82M | 9.50% | +0.0% |
| BlackRock, Inc. | 4.4M | $63M | 7.35% | +1.1% |
| Kynam Capital Management, LP | 3.1M | $44M | 5.15% | +0.0% |
| STATE STREET CORP | 2.5M | $36M | 4.20% | +15.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5M | $35M | 4.10% | new |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.0M | $29M | 3.35% | +4201.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 108.3% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 8,799,071 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2024-09-30 | 2024-11-07 | −$0.69 | — | — | — |
| 2024-06-30 | 2024-08-08 | −$0.75 | — | — | — |
| 2024-03-31 | 2024-05-15 | −$0.86 | — | — | — |
| 2023-09-30 | 2023-11-08 | −$0.91 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
